Economic information and modeling reportBudget impact modelResults
Base case
3 evidence topics · 3 sources
Budget impact model of ficerafusp alfa: base-case results
No evidence found.
Base-case results for first-line pembrolizumab regimens
“In the CPS ≥1 R/M HNSCC population, pembrolizumab monotherapy was dominant vs. EXTREME and TPEx regimens, and cost-effective (at $100,000/QALY threshold) vs. platinum+5-FU ($86,827/QALY) and cisplatin + paclitaxel ($81,473/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab combination therapy in the overall R/M HNSCC population was dominant vs. TPEx regimen, and cost-effective vs. EXTREME regimen ($1769/QALY), platinum+5-FU ($81,989/QALY), and cisplatin + paclitaxel ($89,505/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Base-case results for first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy
“When compared with cetuximab plus chemotherapy, the pembrolizumab monotherapy strategy was dominated by lower cost and better efficacy in all three populations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental costs and quality adjusted life years (QALYs) yielded by pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy were $16016.88 and 0.11 in the total population, and $24467.47 and 0.18 and $30448.46 and 0.20 in the populations with a PD-L1 CPS ≥ 1 and CPS ≥ 20, respectively, leading to ICERs of $147876.14, $134237.84, and $153660.78 per QALY, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote